Foth H, Hellkamp J, Kunellis E M, Kahl G F
Department of Pharmacology and Toxicology, University of Göttingen, FRG.
Drug Metab Dispos. 1990 Nov-Dec;18(6):1011-7.
Elimination kinetics and metabolism of the cytostatic drug 5-fluoro-2'-deoxyuridine (FUDR) were studied in isolated perfused rat lung and in incubated lung slices. The intact organ exhibited a low clearance of 0.2 to 0.8 ml/min and a calculated first-pass extraction of 2 to 7% of the drug inflow. Thus, the pulmonary uptake of the fluorinated nucleoside from the circulation is low. Within 120 min of perfusion, however, 30 to 45% of the initial FUDR dose was metabolized by the isolated rat lung. The nucleobase metabolite 5-fluorouracil (FU) represented almost all FUDR metabolites in the medium, indicating that this metabolic pathway, mediated by thymidine phosphorylase, is active in lung while the enzymic activity for further pyrimidine degradation is low. This was demonstrated in incubated lung slices, which have a high capacity to transform FUDR into FU, comprising 83 to 95% of the metabolites in the medium. The final catabolic metabolite, alpha-fluoro-beta-alanine, was present in trace amounts only. It is concluded that the pulmonary tissue contains a marked "intrinsic" capacity to transform FUDR into FU, while the metabolic activity for catabolism of the nucleobase metabolites FU and 5,6-dihydrouracil is virtually lacking.
在离体灌注大鼠肺和肺切片孵育实验中研究了细胞抑制药物5-氟-2'-脱氧尿苷(FUDR)的消除动力学和代谢情况。完整器官对药物的清除率较低,为0.2至0.8毫升/分钟,计算得出首过提取率为药物流入量的2%至7%。因此,肺从循环中摄取氟化核苷的量较低。然而,在灌注120分钟内,离体大鼠肺将初始FUDR剂量的30%至45%进行了代谢。碱基代谢产物5-氟尿嘧啶(FU)几乎占培养基中所有FUDR代谢产物,这表明由胸苷磷酸化酶介导的这条代谢途径在肺中具有活性,而进一步嘧啶降解的酶活性较低。这在肺切片孵育实验中得到了证实,肺切片将FUDR转化为FU的能力很强,培养基中83%至95%的代谢产物为FU。最终的分解代谢产物α-氟-β-丙氨酸仅以痕量存在。结论是,肺组织具有将FUDR转化为FU的显著“内在”能力,而对于碱基代谢产物FU和5,6-二氢尿嘧啶的分解代谢活性实际上并不存在。